The development of antiviral drugs is a very complex process. Currently, around 50 drugs
have been approved for human use against viruses such as HSV, HIV-1, the cytomegalo …

Anno 2015, the race for developing the ideal therapy, or what is now called “cure,” for
hepatitis C virus infection has continued unabatedly. The targets (NS3/4A protease, NS5A …

The development of new models and tools has led to the discovery and clinical development
of a large number of new anti-hepatitis C virus (HCV) drugs, including direct-acting antivirals …

Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based
therapy has been the mainstay of treatment for HCV. Recently, several direct-acting …

Approximately 120-130 million individuals are chronically infected with hepatitis C virus
(HCV) worldwide, although it is curable by therapy. Until recently, treatment of chronic …

Introduction: Because of the rapid pace of development of new direct-acting antiviral (DAA)
drugs, chronic hepatitis C virus (HCV) infection is now increasingly considered curable …

Hepatitis C virus (HCV) is a global health problem, because infection frequently leads to
chronic hepatitis C eventually progressing to liver cirrhosis and liver cancer. Improved …

Hepatitis C virus (HCV) therapeutics is amidst a revolution. With the recent approval of
sofosbuvir (Sovaldi) and simeprevir (Olysio), clinicians and patients started to recognize that …

The face of future hepatitis C antiviral drug development: Recent biological and virologic
advances and their translation to drug development and clinical practice - ScienceDirect Skip …

Hepatitis C virus (HCV) affects approx. 3% of the world's population and accounts for ca 300
000 deaths per year. 80% of individuals with HCV develop chronic symptoms which, when …